What are the recent trends in market size and growth for the common warts market?
The common warts market size has grown strongly in recent years. It will grow from $2.13 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increased awareness of skin health, a growing incidence of warts, rising demand for non-invasive procedures, increasing use of cryotherapy, and growth in dermatology clinics.
The common warts market size is expected to see strong growth in the next few years. It will grow to $2.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the rising geriatric population, growing prevalence of viral infections, increased adoption of advanced dermatological therapies, growing demand for personalized treatments, and increased consumer preference for homecare solutions. Major trends in the forecast period include advancements in dermatological treatments, expanding healthcare infrastructure, technological advancements in wart removal treatments, enhanced awareness of treatment options, and a shift towards minimally invasive treatments.
Get Your Free Sample of The Global Common Warts Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21154&type=smp
How have varous drivers impacted the growth of the common warts market?
The increasing incidence of viral infections is expected to propel the growth of the common warts market going forward. Viral infections refer to illnesses caused by viruses entering, multiplying, and spreading within the body, affecting cells and immune responses. The increasing incidence of viral infections is driven by globalization, climate change, urbanization, deforestation, and weakened immune responses. Common warts treatment targets the human papillomavirus (HPV) responsible for wart formation, and provides essential support for viral infection patients by reducing the spread of the virus, alleviating discomfort, and promoting healing, thus preventing complications such as secondary infections or scarring while improving the patient’s quality of life. For instance, in 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022 the proportion of PCR-confirmed varicella cases rose by 62%, increasing from 29% to 47% over the past five years. Furthermore, in January 2023, according to the National Foundation for Infectious Diseases, a US-based health organization, annually, there are an estimated 14 million new cases of HPV infection in the United States. Therefore, the increasing incidence of viral infections is driving growth in the common warts market.
What are the primary segments of the common warts market?
The common warts market covered in this report is segmented –
1) By Treatment Method: Cryotherapy, Laser Treatment, Electrosurgery, Topical Medications
2) By Patient Demographics: Children, Adults, Elderly
3) By Disease Stage: Initial Stage, Moderate Stage, Severe Stage
4) By End User: Hospitals, Dermatology Clinics, Home Care
Subsegments:
1) By Cryotherapy: Liquid Nitrogen Therapy, Carbon Dioxide Therapy
2) By Laser Treatment: Pulsed-Dye Laser Therapy, Carbon Dioxide (CO2) Laser Therapy
3) By Electrosurgery: Curettage And Electrosurgical Removal, High-Frequency Electrosurgical Ablation
4) By Topical Medications: Salicylic Acid-Based Therapy, Immunotherapy-Based Topicals, Retinoid-Based Therapy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/common-warts-global-market-report
Which firms are leading the common warts market?
Major companies operating in the common warts market are Major players in the market are AbbVie Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Limited, Perrigo Company plc, Holland & Barrett International Limited, Prestige Consumer Healthcare Inc., Maruho Co. Ltd., Novan Inc., X4 Pharmaceuticals Inc., Aclaris Therapeutics Inc., Verrica Pharmaceuticals Inc., RXi Pharmaceuticals Corporation, Scholl’s Wellness Company, Nielsen BioSciences Inc., Cassiopea S.p.A., Orgenesis Inc., KinoPharma Inc., Naturasil, Veradermics Inc., KinoPharma Co. Ltd.
How will industry trends affect the trajectory of the common warts market?
Major companies operating in the common warts market are focusing on the advancing innovative treatments, such as dermatological therapies, to meet the growing demand for effective and accessible solutions, aiming to improve patient outcomes and expand their market presence in the dermatology sector. Dermatological therapies refer to treatments for skin conditions, including infections, inflammations, and disorders. For instance, in May 2024, Verrica Pharmaceuticals, a US-based pharmaceutical company, entered into a license agreement with Torii Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company. The collaboration aims to fund a global Phase 3 clinical trial for YCANTH, a treatment for common warts. This agreement supports the late-stage development of YCANTH, expanding its potential global reach. Torii Pharmaceuticals will contribute financial resources to advance the study. The collaboration strengthens both companies’ dermatology portfolios and international market presence.
Which geographic trends are shaping the common warts market, and which region has the highest market share?
North America was the largest region in the common warts market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the common warts market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Common Warts Market Report 2025 Offer?
The common warts market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Common warts are non-cancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, and other areas, serving as a defense mechanism for the body in response to the viral infection.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21154
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
